Evaluating oral noncombustible potential-reduced exposure products for smokers
- 16 February 2010
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 12 (4), 336-343
- https://doi.org/10.1093/ntr/ntq003
Abstract
Potential-reduced exposure products (PREPs) are marketed as a way for smokers to continue using tobacco while possibly lessening their tobacco toxicant intake. Some tobacco-based PREPs are combustible and intended to be smoked, while others are noncombustible and intended to be administered orally (e.g., Camel Snus [CS] tobacco sachets and Ariva tobacco tablets). The ability of these noncombustible PREPs to reduce smokers' exposure to cigarette-delivered toxicants and suppress tobacco abstinence symptoms effectively is unclear. Clinical laboratory methods have been used to measure combustible PREP-associated toxicant exposure and abstinence symptom suppression and could be applied to evaluating the effects of orally administered noncombustible PREPs. In this study, 21 smokers (6 women) participated in four 5-day conditions that differed by product used: CS, Ariva, own brand cigarettes, or no tobacco. Measures included expired-air carbon monoxide (CO), the urinary metabolite of nicotine (cotinine), the urinary metabolite of the carcinogen NNK (NNAL-T), and subjective effect ratings. Relative to own brand, all other conditions were associated with CO and cotinine levels that were lower and abstinence symptom ratings that were greater. Only no-tobacco use was associated with significantly lower NNAL levels. Acceptability ratings were also lower in all conditions relative to own brand. Although these oral products reduce exposure to CO, their ineffective abstinence symptom suppression and low acceptability may limit their viability as PREPs. As with combustible PREPs, clinical laboratory study of orally administered noncombustible PREPs will be a valuable part of any comprehensive PREP evaluation strategy.Keywords
This publication has 27 references indexed in Scilit:
- Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokersTobacco Control, 2009
- New and traditional smokeless tobacco: Comparison of toxicant and carcinogen levelsNicotine & Tobacco Research, 2008
- Potential reduced exposure products (PREPs) for smokeless tobacco users: Clinical evaluation methodologyNicotine & Tobacco Research, 2008
- Nicotine delivery, cardiovascular profile, and subjective effects of an oral tobacco product for smokersNicotine & Tobacco Research, 2008
- Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozengeTobacco Control, 2007
- Transdermal nicotine-induced tobacco abstinence symptom suppression: Nicotine dose and smokers' gender.Experimental and Clinical Psychopharmacology, 2006
- Methods to assess potential reduced exposure productsNicotine & Tobacco Research, 2005
- Evaluating acute effects of potential reduced-exposure products for smokers: Clinical laboratory methodologyNicotine & Tobacco Research, 2002
- Changes in Mortality from Smoking in Two American Cancer Society Prospective Studies since 1959Preventive Medicine, 1997
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991